These insights have resulted in a series of clinical trials that have evaluated the therapeutic potential of combining EGFR and MET TKIs in EGFR-mutated NSCLC patients who progressed on osimertinib treatment due to acquired MET alterations. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.